Abstract 91P
Background
To estimate the optimal adjuvant chemotherapy in patients with high-risk stage II and III colon adenocarcinoma, we use a propensity score-matched (PSM), nationwide, population-based cohort study to estimate different adjuvant treatments in high-risk stage II or stage III colon adenocarcinoma.
Methods
We minimized the confounding effects with PSM of sex, age, pathologic stages, tumor locations, total cycles of chemotherapy, and Charlson comorbidity index in various adjuvant treatments outcomes in patients with high-risk stage II and III resctable colon adenocarcinoma from the Taiwan Cancer Registry database by dividing them as follows: group 1, those undergoing surgery alone; group 2, those undergoing adjuvant fluoropyrimidine alone; group 3, those receiving adjuvant oxaliplatin, fluoropyrimidine, and leucovorin (FOLFOX) and group 4 those receiving adjuvant folinic acid, fluorouracil, irinotecan (FOFIRIL).
Results
In both univariate and multivariate Cox regression analyses, adjusted HRs (aHRs) derived for mortality and 95% confidence intervals (CIs), reported as aHR (95% CI), derived for surgery alone, adjuvant fluoropyrimidine alone, and adjuvant FOLFIRI groups compared with the adjuvant FOLFOX group were 1.55 (1.32-1.82), 1.22 (1.05-1.43), and 2.97 (2.43-3.63), respectively. After stratified subgroup analysis, at high-risk stage II, the aHR (95% CI) derived for mortality was 0.52 (0.30-0.89) for the adjuvant fluoropyrimidine alone group compared with the group 3.
Conclusions
Adjuvant fluoropyrimidine alone were more suitable for patients with high-risk stage II colon adenocarcinoma rather than other adjuvant chemotherapy regimens. Adjuvant FOLFOX could be the optimal regimen for patients with pathologic stage III colon adenocarcinoma whatever elderly, sex, or tumor locations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract